TELA Bio, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M | $18.2M | $15.4M | $8.3M |
| Cost of Revenue | $25.6M | $22.4M | $18.0M | $13.6M | $10.3M | $6.7M | $5.9M | $4.5M |
| Gross Profit | $54.3M | $46.5M | $40.1M | $27.0M | $18.8M | $11.2M | $9.3M | $2.9M |
| Gross Margin | 67.7% | 67.1% | 68.6% | 65.3% | 63.9% | 61.7% | 60.0% | 35.6% |
| Operating Expenses | ||||||||
| Research & Development | $9.2M | $8.8M | $9.6M | $8.9M | $6.7M | $4.3M | $4.2M | $4.3M |
| SG&A Expense | $15.7M | $14.7M | $14.9M | $13.9M | $12.5M | $10.1M | $6.2M | $4.9M |
| Operating Income | $-33.8M | $-34.1M | $-44.1M | $-39.0M | $-29.5M | $-25.3M | $-19.2M | $-17.8M |
| Operating Margin | -42.0% | -49.2% | -75.4% | -94.2% | -100.0% | -138.8% | -124.1% | -214.9% |
| Interest Expense | — | — | $5.2M | $4.1M | $3.6M | $3.6M | $3.6M | $1.8M |
| Pretax Income | $-38.6M | $-38.0M | $-46.7M | $-44.3M | — | — | — | — |
| Income Tax Expense | $230.0K | $-144.0K | — | — | — | — | — | — |
| Net Income | $-38.8M | $-37.8M | $-46.7M | $-44.3M | $-33.3M | $-28.8M | $-22.4M | $-21.1M |
| Net Margin | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% | -158.1% | -145.2% | -254.9% |
| EPS (Basic) | $-0.83 | $-1.33 | $-2.04 | $-2.72 | $-2.30 | $-2.23 | $-2.44 | $-14.49 |
| EPS (Diluted) | $-0.83 | $-1.33 | $-2.04 | $-2.72 | $-2.30 | $-2.23 | $-2.44 | $-14.49 |
| Shares Outstanding (Basic) | 46.9M | 28.5M | 22.9M | 16.3M | 14.5M | 12.9M | 12.4M | 2.1M |
| Shares Outstanding (Diluted) | 46.9M | 28.5M | 22.9M | 16.3M | 14.5M | 12.9M | 12.4M | 2.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |